Effects of Indralin on Immunohematological Parameters and DNA Damage in Irradiated ICR (CD-1) Outbred Mice
- Authors: Bushmanov A.Y.1, Osipov A.N.1,2, Ignatov M.A.1, Vorontsova M.D.1, Karaulova T.A.1, Gordeev A.V.1, Yashkina E.I.1, Nikitenko O.V.1,3, Bychkova T.M.1,3, Stavrakova N.M.1, Andrianova I.E.1, Blokhina T.M.1,2, Vorobyeva N.Y.1,2, Ivanov A.A.1,3,4
-
Affiliations:
- State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
- Semenov Institute of Chemical Physics, Russian Academy of Sciences
- Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences
- Joint Institute for Nuclear Research
- Issue: Vol 46, No 11 (2019)
- Pages: 1564-1570
- Section: Modification of Radiation Effects
- URL: https://journals.rcsi.science/1062-3590/article/view/183391
- DOI: https://doi.org/10.1134/S1062359019110104
- ID: 183391
Cite item
Abstract
Abstract—Intragastric administration of radioprotector indralin (B-190 drug) to outbred SPF ICR (CD-1) mice 15 minutes before X-ray irradiation at doses of 6 Gy (LD-10/30), 6.5 Gy, and 7 Gy (LD-100/30) increases the 30-day survival of the animals and positively affects the state of the central organs of immunity and hematopoiesis, as well as the number of peripheral blood leukocytes. In addition, a positive effect on the behavioral reactions of the irradiated animals and striated muscles strength was noted. In addition to these secondary features of the indralin positive effect, a significant reduction of radiation-induced DNA damage in spleenocytes was observed using flow cytometry analysis of phosphorylated histone Н2АХ (γН2АХ) (1 h and eight days after X-ray irradiation) and DNA-comet assay (eight days after X-ray irradiation). The abovementioned methods are recommended for experiments investigating the influence of radioprotective drugs on DNA damage induction and repair in the irradiated organism, as well as for initial searching of potential radioprotectors and assessment of their effectiveness level in clinical practice and experiments.
About the authors
A. Yu. Bushmanov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
A. N. Osipov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences
Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow
M. A. Ignatov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
M. D. Vorontsova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
T. A. Karaulova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
A. V. Gordeev
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
E. I. Yashkina
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
O. V. Nikitenko
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences
Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow
T. M. Bychkova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences
Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow
N. M. Stavrakova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
I. E. Andrianova
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency
Email: a1931192@mail.ru
Russian Federation, Moscow
T. M. Blokhina
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences
Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow
N. Yu. Vorobyeva
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Semenov Institute of Chemical Physics, Russian Academy of Sciences
Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow
A. A. Ivanov
State Research Center—Burnasyan Federal Medical Biophysical Center of Federal Medical Biological Agency; Federal State Budgetary Institution of Science “Russian Federation State Scientific Center—Institute of Biomedical Problems,” Russian Academy of Sciences; Joint Institute for Nuclear Research
Author for correspondence.
Email: a1931192@mail.ru
Russian Federation, Moscow; Moscow; Dubna